Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Carnitine levels and mutations in the SLC22A5 gene in Faroes patients with Parkinson's disease.

Neuroscience letters - 14 May 2018

Crooks Súsanna A, Bech Sára, Halling Jónrit, Christiansen Debes H, Ritz Beate, Petersen Maria Skaalum

Abstract excerpt

INTRODUCTION: Mitochondrial dysfunction, oxidative stress and energy production have been implicated in the etiology of Parkinson's disease (PD). Several agents are under investigation for potential neuroprotective effects including acetyl-l-carnitine (ALC). OBJECTIVE: To investigate whether low carnitine levels and mutations in the SLC22A5 gene encoding the carnitine transporter are associates with PD risk in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Cardiomyopathies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carnitine

Share to Denmark

Share to Hyperammonemia

Share to Muscular Diseases

Share to Parkinson Disease

Share to Solute Carrier Family 22 Member 5

Source

Identifiers

PMID: 29614331
DOI: 10.1016/j.neulet.2018.03.064

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Carnitine levels and mutations in the SLC22A5 gene in Faroes patients with Parkinson's disease.PMID 29614331Read ↗

Carnitine levels in 26,462 individuals from the nationwide screening program for primary carnitine deficiency in the Faroe Islands.Semantic proximity Read ↗

Residual OCTN2 transporter activity, carnitine levels and symptoms correlate in patients with primary carnitine deficiencySemantic proximity Read ↗

Parkinson's disease, genetic variability and the Faroe Islands.Semantic proximity Read ↗

[Carnitine transporter deficiency is a hereditary disease with a high incidence in the Faroe Islands].Semantic proximity Read ↗

Primary Carnitine Deficiency and Newborn Screening for Disorders of the Carnitine Cycle.Semantic proximity Read ↗

Primary Carnitine deficiency in the Faroe Islands: health and cardiac status in 76 adult patients diagnosed by screeningSemantic proximity Read ↗

Increased risk of sudden death in untreated primary carnitine deficiencySemantic proximity Read ↗

Functional and molecular studies in primary carnitine deficiency.Semantic proximity Read ↗

Genotype-phenotype correlation in primary carnitine deficiency.Semantic proximity Read ↗

Abnormally low serum acylcarnitine levels in narcolepsy patients.Semantic proximity Read ↗

[Mutational analysis of SLC22A5 gene in eight patients with systemic primary carnitine deficiency].Semantic proximity Read ↗

Genetic predisposition to Parkinson's disease: CYP2D6 and HFE in the Faroe Islands.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.